- Viracta Therapeutics Inc To Host R&D Day TranscriptOct 04, 2023
- Viracta Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Viracta Therapeutics Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2023
- Viracta Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) TranscriptApr 26, 2023
- Viracta Therapeutics Inc To Discuss Nana-val For The Treatment Of Advanced Epstein-Barr Virus-Positive Solid Tumors Call TranscriptApr 27, 2022
- Sunesis Pharmaceuticals, Inc., Viracta Therapeutics, Inc. - M&A Call TranscriptNov 30, 2020
- Q3 2020 Sunesis Pharmaceuticals Inc Earnings Call TranscriptNov 16, 2020Earnings
- Q2 2020 Sunesis Pharmaceuticals Inc Earnings Call TranscriptAug 11, 2020Earnings
- Q1 2020 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2020Earnings
- Q4 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMar 10, 2020Earnings
- Sunesis Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Scottsdale TranscriptNov 13, 2019
- Q3 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptNov 12, 2019Earnings
- Q2 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptAug 07, 2019Earnings
- Q1 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMay 08, 2019Earnings
- Sunesis Pharmaceuticals Inc at Oppenheimer Healthcare Conference TranscriptMar 19, 2019
- Q4 2018 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMar 07, 2019Earnings
Viracta Therapeutics Inc To Discuss Nana-val For The Treatment Of Advanced Epstein-Barr Virus-Positive Solid Tumors Call Transcript
Good morning, and welcome to the Viracta Therapeutics KOL Webinar. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Viracta website following the conclusion of the event. I'd now like to turn the call over to your host, Dr. Ivor Royston, President and Chief Executive Officer of Viracta Therapeutics. Please go ahead, Ivor.
Okay. Thank you very much, (inaudible). It is my pleasure to be speaking with you at our KOL event today. We are pleased to partner with LifeSci Advisors for this event and what is an exciting time for Viracta.
Next slide. Before we begin, I'd like to remind you that certain statements in this presentation may be forward looking, and I invite you to visit our website to review our SEC filings and to read about the risks associated with such statements. For those of you who may be new to Viracta, the company lies at the intersection of virology and oncology, targeting virus-associated malignancies. We
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)